Page last updated: 2024-12-04

pk 11195

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

PK-11195 : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 1-(2-chlorophenyl)isoquinoline-3-carboxylic acid with the amino group of sec-butylmethylamine [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID1345
CHEMBL ID15313
CHEMBL ID481537
CHEBI ID73290
SCHEMBL ID117124
MeSH IDM0114262

Synonyms (81)

Synonym
unii-ynf83vn1rl
ynf83vn1rl ,
HMS3266H15
BRD-A41451487-001-01-3
smr000058427
1-(2-chlorophenyl)-n-methyl-n-(1-methylpropyl)-3-isoquinolinecarboxamide
pk-11195
MLS000028483
rp 52028
brn 4264456
pk11195
3-isoquinolinecarboxamide, 1-(2-chlorophenyl)-n-methyl-n-(1-methylpropyl)-
bdbm22032
chembl15313
[3h]pk 11195
n-(butan-2-yl)-1-(2-chlorophenyl)-n-methylisoquinoline-3-carboxamide
EU-0100198
pk 11195
PDSP2_000632
LOPAC0_000198
BIOMOL-NT_000287 ,
PDSP1_000637
NCGC00024720-04
BPBIO1_001278
NCGC00024720-03
NCGC00024720-02
85532-75-8
85340-56-3
NCGC00015205-03
1-(2-chlorophenyl)-n-methyl-n-(1-methylpropyl)
C 0424
NCGC00015205-06
CHEMBL481537
chebi:73290 ,
n-butan-2-yl-1-(2-chlorophenyl)-n-methylisoquinoline-3-carboxamide
HMS3260H17
tox21_300620
NCGC00254354-01
cas-85532-75-8
dtxcid5021097
dtxsid7041097 ,
CCG-204293
HMS2234C05
n-sec-butyl-1-(2-chlorophenyl)-n-methylisoquinoline-3-carboxamide
NCGC00015205-05
NCGC00015205-04
NCGC00015205-08
NCGC00015205-07
LP00198
HMS3372J02
rp-52028
n-methyl-n-(1-methylpropyl)-1-(2-chlorophenyl)isoquinoline-3-carboxamide
MLS006010699
SCHEMBL117124
tox21_500198
NCGC00260883-01
1-(2-chloro-phenyl)-isoquinoline-3-carboxylic acid sec-butyl-methyl-amide
HB0922
c21h21cln2o
gtpl8703
AKOS024458600
sr-01000076240
SR-01000076240-1
SR-01000076240-3
FT-0724157
HY-19567
CS-0015789
n-(sec-butyl)-1-(2-chlorophenyl)-n-methylisoquinoline-3-carboxamide
pk-11195; rp-52028
EX-A2448
HMS3675O10
HMS3411O10
Q7119490
BRD-A41451487-001-04-7
SDCCGSBI-0050186.P002
HMS3870J13
NCGC00015205-14
MS-25479
BM166506
E98630
pk11195,(r)-(-)-

Research Excerpts

Overview

PK 11195 is an isoquinoline carboxamide derivative that potently displaces [3H]-Ro 5-4864 from its binding sites. It is a high-affinity ligand for the PBR.

ExcerptReferenceRelevance
"PK 11195 is an isoquinoline carboxamide derivative that potently displaces [3H]-Ro 5-4864 from its binding sites."( Pro- and anti-convulsant properties of PK 11195, a ligand for benzodiazepine binding sites: development of tolerance.
File, SE, 1984
)
1.26
"PK 11195 is a high-affinity ligand for the PBR."( Biodistribution and dosimetry of [123I]iodo-PK 11195: a potential agent for SPET imaging of the peripheral benzodiazepine receptor.
De Vos, F; Dierckx, RA; Dumont, F; Jansen, H; Korf, J; Santens, P; Slegers, G; Thierens, H; Versijpt, J, 2000
)
1.29
"PK 11195 is a selective ligand for the peripheral-type benzodiazepine binding site (PTBBS). "( The distribution of radioactivity in brains of rats given [N-methyl-11C]PK 11195 in vivo after induction of a cortical ischaemic lesion.
Bateman, DM; Cremer, JE; Cullen, BM; Hume, SP; Luthra, SK; Manjil, LG; Myers, R; Pike, VW; Turton, DR, 1992
)
1.96
"PK 11195 is a selective ligand for the peripheral-type benzodiazepine binding sites which exhibits anti-conflict activity in animals. "( Pilot study of PK 11195, a selective ligand for the peripheral-type benzodiazepine binding sites, in inpatients with anxious or depressive symptomatology.
Ansseau, M; Cerfontaine, JL; Papart, P; von Frenckell, R, 1991
)
2.08
"PK 11195 is a selective and specific ligand for the peripheral-type benzodiazepine binding site. "( Macrophage and astrocyte populations in relation to [3H]PK 11195 binding in rat cerebral cortex following a local ischaemic lesion.
Cremer, JE; Cullen, BM; Frackowiak, RS; Manjil, LG; Myers, R; Price, GW, 1991
)
1.97

Effects

ExcerptReferenceRelevance
"PK 11195 which has been shown to inhibit the binding of Ro 5-4864 to cardiac muscle did not antagonize this vasodilatory effect of Ro 5-4864 but increased coronary flow by itself."( Benzodiazepine Ro 5-4864 increases coronary flow.
French, JF; Grupp, IL; Matlib, MA, 1987
)
0.99

Treatment

PK 11195 pretreatment (12.5 and 25 mg/kg) reverses anxiety-induced PAG changes. Pretreatment with Lorazepam reversed its effects in the heart but not in the brain.

ExcerptReferenceRelevance
"PK 11195 cell treatment activated an autophagic pathway followed by apoptosis mediated by the modulation of the mitochondrial permeability transition."( PK 11195 differentially affects cell survival in human wild-type and 18 kDa translocator protein-silenced ADF astrocytoma cells.
Chelli, B; Costa, B; Da Pozzo, E; Gremigni, V; Lena, A; Martini, C; Rainaldi, G; Rechichi, M; Rossi, L; Salvetti, A; Scatena, F; Spinetti, F; Vanacore, R, 2008
)
2.51
"2. PK 11195 pretreatment (12.5 and 25 mg/kg) reverses anxiety-induced PAG changes."( Effect of PK 11195, an antagonist of benzodiazepine receptors, on platelet aggregation in a model of anxiety in the rat.
Castillo, JR; Fernández-Alonso, A; Hevia, A; Serrano, JS, 1988
)
1.19
"Pretreatment with PK 11195 (25 µM) exhibited significant protective capacity on CoCl2-induced alterations in the mentioned processes."( The Effect of the Classical TSPO Ligand PK 11195 on In Vitro Cobalt Chloride Model of Hypoxia-like Condition in Lung and Brain Cell Lines.
Amara, R; Gavish, M; Monga, S; Weizman, A; Zeineh, N, 2022
)
1.31
"Pretreatment of PK 11195 suppressed while AC-5216 potentiated CSM-induced apoptosis, collapse of ΔΨm, elevation of cytoplasmic/mitochondrial ROS levels and IL-8 release."( Cigarette smoke induces apoptosis via 18 kDa translocator protein in human bronchial epithelial cells.
Cui, Y; Ip, MSM; Liang, Y; Mak, JCW, 2021
)
0.96
"Pretreatment with PK 11195 before Lorazepam reversed its effects in the heart but not in the brain."( The stress-induced reduction in monoamine oxidase (MAO) A activity is reversed by benzodiazepines: role of peripheral benzodiazepine receptors.
Armando, I; Barontini, MB; Lemoine, AP; Segura, ET, 1993
)
0.61

Toxicity

ExcerptReferenceRelevance
"Hemin was shown to be toxic for the Caco-2 cell line in a concentration and time dependent manner."( Cytotoxic effect of hemin in colonic epithelial cell line: involvement of 18 kDa translocator protein (TSPO).
Corsi, L; Dongmo, BM; Ferrarini, F; Gemelli, C; Grande, A, 2014
)
0.4
" The presented data suggest that TSPO might contribute to protect cells from potential toxic compounds such as free tetrapyrroles, candidating this receptor as a survival receptor protein."( Cytotoxic effect of hemin in colonic epithelial cell line: involvement of 18 kDa translocator protein (TSPO).
Corsi, L; Dongmo, BM; Ferrarini, F; Gemelli, C; Grande, A, 2014
)
0.4

Pharmacokinetics

ExcerptReferenceRelevance
" Despite its use in clinical research, no studies on the imaging properties and pharmacokinetic analysis of (11)C-PBR28 in rodent models of neuroinflammation have been published yet."( Pharmacokinetic Analysis of 11C-PBR28 in the Rat Model of Herpes Encephalitis: Comparison with (R)-11C-PK11195.
de Vries, EF; Dierckx, RA; Doorduin, J; Feltes, PK; Moriguchi Jeckel, CM; Parente, A; Sijbesma, JW; Vállez García, D, 2016
)
0.43

Bioavailability

ExcerptReferenceRelevance
" After oral ingestion the pharmacokinetics of PK 11195 were linear over the range of 100-400 mg single oral doses with a stable absolute bioavailability (33%)."( Pharmacokinetics and effects on exercise heart rate of PK 11195 (52028 RP), an antagonist of peripheral benzodiazepine receptors, in healthy volunteers.
Ferry, A; Jaillon, P; Jozefczak, C; Lecocq, B; Lecocq, V, 1989
)
0.78
"(18)F-DPA-714 appears to be an attractive alternative to (11)C-PK11195 because of its increased bioavailability in brain tissue and its reduced nonspecific binding."( Comparative evaluation of the translocator protein radioligands 11C-DPA-713, 18F-DPA-714, and 11C-PK11195 in a rat model of acute neuroinflammation.
Boutin, H; Chauveau, F; Damont, A; Dollé, F; Hinnen, F; James, M; Kassiou, M; Kuhnast, B; Tavitian, B; Van Camp, N, 2009
)
0.35
", ip) indicate that the liver is the primary site of biotransformation of the compound, suggesting that both 22a and its metabolite(s) are active, compensating probably low bioavailability of the parent molecule."( Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
Bednarski, M; Gunia-Krzyżak, A; Marona, H; Nitek, W; Pękala, E; Powroźnik, B; Słoczyńska, K; Walczak, M; Waszkielewicz, AM; Żesławska, E, 2016
)
0.43
"Cell membrane permeability is an important determinant for oral absorption and bioavailability of a drug molecule."( Highly predictive and interpretable models for PAMPA permeability.
Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR, 2017
)
0.46
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

No significant tolerance developed to the anticonvulsant action of PK 11195 (30 mg kg-1) even after 25 days of dosing daily.

ExcerptRelevanceReference
" Heart rate and blood pressure were recorded at rest and during exercise tests which were performed at 0, 1, 3, 6 and 24 h after dosing on each study day."( Pharmacokinetics and effects on exercise heart rate of PK 11195 (52028 RP), an antagonist of peripheral benzodiazepine receptors, in healthy volunteers.
Ferry, A; Jaillon, P; Jozefczak, C; Lecocq, B; Lecocq, V, 1989
)
0.52
" Although experimental studies have shown interaction of the drug with the calcium channels, our study did not demonstrate any anti-ischemic effect with the dosage used."( [Absence of an anti-ischemic effect of the peripheral benzodiazepine receptor antagonist PK 11195. Study by atrial stimulation in man].
Drobinski, G; Eugène, L; Grosgogeat, Y; Lechat, P,
)
0.35
" No significant tolerance developed to the anticonvulsant action of PK 11195 (30 mg kg-1) even after 25 days of dosing daily."( Pro- and anti-convulsant properties of PK 11195, a ligand for benzodiazepine binding sites: development of tolerance.
File, SE, 1984
)
0.77
" FLU evoked dose-related tonic-clonic and clonic convulsions (five out of six rats), whereas PK (10 mg/kg) induced convulsions in only one rat (out of five); tachypnea tended to increase with the dose of both FLU and PK; twitches and jerks, backing and writhing had a significant regression on the dose of FLU; rearing tended to decrease with the dose of PK whereas FLU-evoked head bobbing and PK-evoked twitches and jerks had inverse U-shaped dose-response curves."( Comparison of abstinence syndromes precipitated by flumazenil and PK 11195 in female diazepam-dependent rats.
Jing, X; Sloan, JW; Wala, EP, 1997
)
0.53
" It appears that in female rats, at least at these doses and dosing schedules, there is no correlation between the impact of chronic in vivo exposure to these agents on PBR density and ovarian and adrenal hormone levels."( Peripheral-type benzodiazepine receptor ligands and serum steroid hormones.
Gavish, M; Leschiner, S; Schlegel, W; Weizman, R, 1997
)
0.3
"These studies were undertaken to 1) determine whether repeated dosing with the peripheral benzodiazepine antagonist PK 11195 alters its ability to precipitate withdrawal abstinence in diazepam-dependent rats; 2) whether the administration of PK 11195 and the central benzodiazepine antagonist, flumazenil, 3 days apart to the same rat produces an ordering effect in the intensity of withdrawal abstinence; 3) whether there are gender differences in these effects."( The pharmacodynamics of PK 11195 in diazepam-dependent male and female rats.
Holtman, JR; Jing, X; Sloan, JW; Wala, EP, 2000
)
0.82
" These studies consisted of single-dose and steady-state dosing regimen studies, the latter to assess drug distribution in normal brain and brain tumors."( Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft model.
Adams, AL; Gallo, JM; Guo, P; Guo, Z; Li, S; Ma, J, 2001
)
0.31
" These results suggest that neither drug has therapeutic efficacy, however dosing and/or administration issues may have played a role."( Melatonin and minocycline for combinatorial therapy to improve functional and histopathological deficits following traumatic brain injury.
Kelso, ML; Pauly, JR; Scheff, NN; Scheff, SW, 2011
)
0.37
" Specifically, the TSPO ligand RT significantly fitted both with steroidogenic efficacy (Emax) and with area under the dose-response curve, a parameter combining drug potency and efficacy."( TSPO ligand residence time: a new parameter to predict compound neurosteroidogenic efficacy.
Barresi, E; Costa, B; Da Pozzo, E; Da Settimo, F; Giacomelli, C; Martini, C; Taliani, S, 2016
)
0.43
"12mg/kg/infusion) were tested, producing an inverted U-shaped dose-response curve."( The differential effects of alprazolam and oxazepam on methamphetamine self-administration in rats.
Goeders, NE; Guerin, GF; Spence, AL, 2016
)
0.43
"Oxazepam significantly reduced methamphetamine self-administration as demonstrated by a downward shift of the dose-response curve."( The differential effects of alprazolam and oxazepam on methamphetamine self-administration in rats.
Goeders, NE; Guerin, GF; Spence, AL, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
isoquinolinesA class of organic heteropolycyclic compound consisting of isoquinoline and its substitution derivatives.
monocarboxylic acid amideA carboxamide derived from a monocarboxylic acid.
aromatic amideAn amide in which the amide linkage is bonded directly to an aromatic system.
monochlorobenzenesAny member of the class of chlorobenzenes containing a mono- or poly-substituted benzene ring in which only one substituent is chlorine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (59)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency28.18380.044717.8581100.0000AID485341
Chain A, Ferritin light chainEquus caballus (horse)Potency31.62285.623417.292931.6228AID2323
endonuclease IVEscherichia coliPotency15.84890.707912.432431.6228AID1708
RAR-related orphan receptor gammaMus musculus (house mouse)Potency8.35620.006038.004119,952.5996AID1159523
Fumarate hydrataseHomo sapiens (human)Potency10.49040.00308.794948.0869AID1347053
TDP1 proteinHomo sapiens (human)Potency23.72460.000811.382244.6684AID686978; AID686979
AR proteinHomo sapiens (human)Potency32.14080.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743042; AID743054; AID743063
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency19.95260.011212.4002100.0000AID1030
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency44.36160.000657.913322,387.1992AID1259377
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency1.67010.001022.650876.6163AID1224838; AID1224893
regulator of G-protein signaling 4Homo sapiens (human)Potency0.94570.531815.435837.6858AID504845
EWS/FLI fusion proteinHomo sapiens (human)Potency16.48690.001310.157742.8575AID1259252; AID1259253; AID1259256
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency35.54560.000214.376460.0339AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency23.12000.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency6.32100.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency27.21500.001530.607315,848.9004AID1224819; AID1224820; AID1224841; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency31.68010.375827.485161.6524AID743220
pregnane X nuclear receptorHomo sapiens (human)Potency0.49770.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency35.54560.000229.305416,493.5996AID743069; AID743078
polyproteinZika virusPotency10.49040.00308.794948.0869AID1347053
ParkinHomo sapiens (human)Potency20.59620.819914.830644.6684AID720572
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency39.88280.001019.414170.9645AID743094
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency28.23490.023723.228263.5986AID743222
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency39.81070.035520.977089.1251AID504332
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency39.53730.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency32.46100.001628.015177.1139AID1224843; AID1224895
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency35.545619.739145.978464.9432AID1159509
Bloom syndrome protein isoform 1Homo sapiens (human)Potency25.11890.540617.639296.1227AID2364; AID2528
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency75.686323.934123.934123.9341AID1967
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency32.64270.00419.984825.9290AID504444
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency35.23770.000323.4451159.6830AID743065; AID743067
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency35.23770.000627.21521,122.0200AID743202; AID743219
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency89.12510.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency1.25890.004611.374133.4983AID624297
neuropeptide S receptor isoform AHomo sapiens (human)Potency0.19950.015812.3113615.5000AID1461
TAR DNA-binding protein 43Homo sapiens (human)Potency28.18381.778316.208135.4813AID652104
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency0.00540.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)IC50 (µMol)3.33670.00010.507510.0000AID40237; AID40238; AID42334
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Ki1.00000.00020.656110.0000AID52213
Cytochrome P450 3A4Homo sapiens (human)Ki0.00710.00011.41629.9000AID613582
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)IC50 (µMol)3.33670.00010.507510.0000AID40237; AID40238; AID42334
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Ki1.00000.00020.656110.0000AID52213
Translocator proteinRattus norvegicus (Norway rat)IC50 (µMol)0.00300.00010.63934.8100AID1285618; AID1336310; AID318341; AID39904; AID39906; AID39907; AID40086; AID40100; AID40229; AID40238; AID42334
Translocator proteinRattus norvegicus (Norway rat)Ki0.00500.00010.65108.9300AID1156185; AID1198724; AID1236028; AID1798152; AID1849526; AID1894698; AID275802; AID39929; AID40374; AID593590; AID619230; AID678665; AID685342
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)IC50 (µMol)3.33670.00010.507510.0000AID40237; AID40238; AID42334
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Ki1.00000.00020.656110.0000AID52213
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)IC50 (µMol)3.33670.00010.505710.0000AID40237; AID40238; AID42334
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Ki1.00000.00020.561410.0000AID52213
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)IC50 (µMol)3.33670.00010.497310.0000AID40237; AID40238; AID42334
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Ki1.00000.00020.635210.0000AID52213
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)IC50 (µMol)3.33670.00010.507510.0000AID40237; AID40238; AID42334
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Ki1.00000.00020.621710.0000AID52213
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)IC50 (µMol)3.33670.00010.498810.0000AID40237; AID40238; AID42334
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Ki1.00000.00020.675810.0000AID52213
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)IC50 (µMol)3.33670.00010.504610.0000AID40237; AID40238; AID42334
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Ki1.00000.00020.646910.0000AID52213
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)IC50 (µMol)3.33670.00010.507510.0000AID40237; AID40238; AID42334
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Ki1.00000.00020.656110.0000AID52213
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)IC50 (µMol)3.33670.00010.507510.0000AID40237; AID40238; AID42334
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Ki1.00000.00020.656110.0000AID52213
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)IC50 (µMol)3.33670.00010.507510.0000AID40237; AID40238; AID42334
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Ki1.00000.00020.671210.0000AID52213
Translocator proteinHomo sapiens (human)IC50 (µMol)0.16450.00030.13020.4900AID1338613; AID346405; AID570603
Translocator proteinHomo sapiens (human)Ki0.02060.00020.02160.0988AID1198725; AID1506534; AID1506535; AID1695085; AID1695086; AID346405; AID613582
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)IC50 (µMol)3.33670.00010.506510.0000AID40237; AID40238; AID42334
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Ki1.00000.00020.557710.0000AID52213
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)IC50 (µMol)3.33670.00010.505710.0000AID40237; AID40238; AID42334
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Ki1.00000.00020.640310.0000AID52213
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)IC50 (µMol)3.33670.00010.507510.0000AID40237; AID40238; AID42334
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Ki1.00000.00020.570810.0000AID52213
Nuclear receptor subfamily 1 group I member 3 Homo sapiens (human)IC50 (µMol)0.39000.08001.38974.0780AID1276954
GABA theta subunitRattus norvegicus (Norway rat)IC50 (µMol)3.33670.00010.507510.0000AID40237; AID40238; AID42334
GABA theta subunitRattus norvegicus (Norway rat)Ki1.00000.00020.656110.0000AID52213
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)IC50 (µMol)3.33670.00010.507510.0000AID40237; AID40238; AID42334
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Ki1.00000.00020.656110.0000AID52213
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Kd0.00200.00020.56294.4668AID39918
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Kd0.00200.00020.56294.4668AID39918
Translocator proteinRattus norvegicus (Norway rat)Kd0.00130.00060.82834.0000AID368146; AID39918
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Kd0.00200.00020.56294.4668AID39918
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Kd0.00200.00020.56294.4668AID39918
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)Kd0.00200.00012.29338.5114AID39918
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Kd0.00200.00020.56294.4668AID39918
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Kd0.00200.00020.56294.4668AID39918
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Kd0.00200.00020.56294.4668AID39918
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Kd0.00200.00020.56294.4668AID39918
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Kd0.00200.00020.56294.4668AID39918
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Kd0.00200.00020.56294.4668AID39918
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Kd0.00200.00020.56294.4668AID39918
Translocator proteinHomo sapiens (human)Kd0.00810.00110.00480.0111AID1338644; AID1503637; AID408746
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Kd0.00200.00020.56294.4668AID39918
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Kd0.00200.00020.56294.4668AID39918
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Kd0.00200.00020.56294.4668AID39918
GABA theta subunitRattus norvegicus (Norway rat)Kd0.00200.00020.56294.4668AID39918
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Kd0.00200.00020.56294.4668AID39918
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
prostaglandin E2 receptor EP2 subtypeHomo sapiens (human)Active Concentration20.000020.000020.000020.0000AID1421
Translocator proteinHomo sapiens (human)Activity0.00060.00060.00510.0073AID368140
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (81)

Processvia Protein(s)Taxonomy
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
protein targeting to mitochondrionTranslocator proteinHomo sapiens (human)
C21-steroid hormone biosynthetic processTranslocator proteinHomo sapiens (human)
heme biosynthetic processTranslocator proteinHomo sapiens (human)
monoatomic anion transportTranslocator proteinHomo sapiens (human)
chloride transportTranslocator proteinHomo sapiens (human)
steroid metabolic processTranslocator proteinHomo sapiens (human)
glial cell migrationTranslocator proteinHomo sapiens (human)
response to xenobiotic stimulusTranslocator proteinHomo sapiens (human)
response to manganese ionTranslocator proteinHomo sapiens (human)
response to vitamin B1Translocator proteinHomo sapiens (human)
peripheral nervous system axon regenerationTranslocator proteinHomo sapiens (human)
sterol transportTranslocator proteinHomo sapiens (human)
adrenal gland developmentTranslocator proteinHomo sapiens (human)
negative regulation of protein ubiquitinationTranslocator proteinHomo sapiens (human)
regulation of cholesterol transportTranslocator proteinHomo sapiens (human)
response to progesteroneTranslocator proteinHomo sapiens (human)
negative regulation of tumor necrosis factor productionTranslocator proteinHomo sapiens (human)
response to testosteroneTranslocator proteinHomo sapiens (human)
regulation of cell population proliferationTranslocator proteinHomo sapiens (human)
cholesterol homeostasisTranslocator proteinHomo sapiens (human)
positive regulation of apoptotic processTranslocator proteinHomo sapiens (human)
negative regulation of nitric oxide biosynthetic processTranslocator proteinHomo sapiens (human)
behavioral response to painTranslocator proteinHomo sapiens (human)
regulation of steroid biosynthetic processTranslocator proteinHomo sapiens (human)
positive regulation of mitochondrial depolarizationTranslocator proteinHomo sapiens (human)
positive regulation of calcium ion transportTranslocator proteinHomo sapiens (human)
contact inhibitionTranslocator proteinHomo sapiens (human)
positive regulation of glial cell proliferationTranslocator proteinHomo sapiens (human)
negative regulation of glial cell proliferationTranslocator proteinHomo sapiens (human)
positive regulation of programmed necrotic cell deathTranslocator proteinHomo sapiens (human)
cellular response to lipopolysaccharideTranslocator proteinHomo sapiens (human)
cellular response to zinc ionTranslocator proteinHomo sapiens (human)
cellular hypotonic responseTranslocator proteinHomo sapiens (human)
maintenance of protein location in mitochondrionTranslocator proteinHomo sapiens (human)
negative regulation of mitophagyTranslocator proteinHomo sapiens (human)
negative regulation of ATP metabolic processTranslocator proteinHomo sapiens (human)
response to acetylcholineTranslocator proteinHomo sapiens (human)
positive regulation of reactive oxygen species metabolic processTranslocator proteinHomo sapiens (human)
negative regulation of corticosterone secretionTranslocator proteinHomo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
osteoblast differentiationNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
signal transductionNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
cell differentiationNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (44)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
androgen bindingTranslocator proteinHomo sapiens (human)
protein bindingTranslocator proteinHomo sapiens (human)
benzodiazepine receptor activityTranslocator proteinHomo sapiens (human)
cholesterol bindingTranslocator proteinHomo sapiens (human)
transmembrane transporter bindingTranslocator proteinHomo sapiens (human)
cholesterol transfer activityTranslocator proteinHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
DNA-binding transcription factor activityNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
nuclear receptor activityNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
protein bindingNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
zinc ion bindingNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Processvia Protein(s)Taxonomy
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
mitochondrionTranslocator proteinHomo sapiens (human)
mitochondrial outer membraneTranslocator proteinHomo sapiens (human)
cytosolTranslocator proteinHomo sapiens (human)
intracellular membrane-bounded organelleTranslocator proteinHomo sapiens (human)
extracellular exosomeTranslocator proteinHomo sapiens (human)
endoplasmic reticulumTranslocator proteinHomo sapiens (human)
membraneTranslocator proteinHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
nucleusNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
nucleoplasmNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
cytoplasmNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
cytosolNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
cytoskeletonNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
chromatinNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
nucleusNuclear receptor subfamily 1 group I member 3 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (213)

Assay IDTitleYearJournalArticle
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID686947qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Identification of potent Yes1 kinase inhibitors using a library screening approach.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID169249Percent inhibition of [3H]flumazenil binding to rat GABA-A central benzodiazepine receptor 10 uM2004Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7
N,N-dialkyl-2-phenylindol-3-ylglyoxylamides. A new class of potent and selective ligands at the peripheral benzodiazepine receptor.
AID685342Displacement of [3H]PK11195 from TSPO receptor in rat Sprague-Dawley kidney membranes after 1 hr by liquid scintillation counting2012Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18
Design, synthesis and structure-activity relationships of novel benzoxazolone derivatives as 18 kDa translocator protein (TSPO) ligands.
AID613583Induction of pregnenolone synthesis in rat C6 cells at 40 uM after 2 hrs by ELISA relative to control2011Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16
Synthesis of 6-[¹⁸F]fluoro-PBR28, a novel radiotracer for imaging the TSPO 18 kDa with PET.
AID306156Induction of reactive oxygen species response in Jurkat cells at 75 uM in presence of Mn(III)tetrakis(4-benzoic acid)porphyrin after 1 hr2007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
Inhibition of the mitochondrial F1F0-ATPase by ligands of the peripheral benzodiazepine receptor.
AID318341Displacement of [3H]PK115 from peripheral benzodiazepine receptor in Sprague-Dawley rat cortical membrane2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Synthesis and structure-activity relationship studies in peripheral benzodiazepine receptor ligands related to alpidem.
AID363485Displacement of [3H]PK11195 from translocator protein in rat kidney mitochondrial membrane2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Anxiolytic-like effects of N,N-dialkyl-2-phenylindol-3-ylglyoxylamides by modulation of translocator protein promoting neurosteroid biosynthesis.
AID1338643Displacement of [3H]PK11195 from TSPO in Sprague-Dawley rat cerebral cortex membranes after 60 mins by microbeta liquid scintillation counting method2017European journal of medicinal chemistry, Jan-05, Volume: 125Discovery of benzimidazole derivatives as modulators of mitochondrial function: A potential treatment for Alzheimer's disease.
AID461672Lipophilicity, log P by Abraham acidity parameter2010Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3
New iodinated quinoline-2-carboxamides for SPECT imaging of the translocator protein.
AID613587Ex vivo binding affinity to TSPO in AMPA lesioned rat assessed as increase in ipsi to contralateral ratio by auto radiography2011Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16
Synthesis of 6-[¹⁸F]fluoro-PBR28, a novel radiotracer for imaging the TSPO 18 kDa with PET.
AID42314Ability to inhibit [3H]-PK 11195 binding to peripheral-type benzodiazepine receptor(PBR) in rat cerebral cortex homogenate.1996Journal of medicinal chemistry, Jul-19, Volume: 39, Issue:15
Cardiovascular characterization of pyrrolo[2,1-d][1,5]benzothiazepine derivatives binding selectively to the peripheral-type benzodiazepine receptor (PBR): from dual PBR affinity and calcium antagonist activity to novel and selective calcium entry blocker
AID264321Decrease in uptake in iv dosed Sprague-Dawley rat brain cerebellum after 30 mins per gram of wet tissue in presence of 1 mg/kg DAA11062006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
[2-11C]isopropyl-, [1-11C]ethyl-, and [11C]methyl-labeled phenoxyphenyl acetamide derivatives as positron emission tomography ligands for the peripheral benzodiazepine receptor: radiosynthesis, uptake, and in vivo binding in brain.
AID524795Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID277912Displacement of [11C]flumazenil from CBR in Sprague-Dawley rat brain2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
N-(5-Fluoro-2-phenoxyphenyl)-N-(2-[(131)I]iodo-5-me thoxybenzyl)acetamide: a potent iodinated radioligand for the peripheral-type benzodiazepine receptor in brain.
AID40237In vitro displacement of [11C]Flumazenil from (CBR) central GABA-A benzodiazepine receptor of rat brain2003Bioorganic & medicinal chemistry letters, Jan-20, Volume: 13, Issue:2
[18F]FMDAA1106 and [18F]FEDAA1106: two positron-emitter labeled ligands for peripheral benzodiazepine receptor (PBR).
AID672796Increase in pregnenolone production in rat C6 glioma cells at 40 uM after 2 hrs by ELISA2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Synthesis and biological evaluation of 4-phenylquinazoline-2-carboxamides designed as a novel class of potent ligands of the translocator protein.
AID626987Displacement of [3H]PK11195 from TSPO in Sprague-Dawley rat brain homogenates after 90 mins by liquid scintillation spectrometry2011Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20
Synthesis and structure-activity relationship studies in translocator protein ligands based on a pyrazolo[3,4-b]quinoline scaffold.
AID39918Binding affinity constant for peripheral (mitochondrial) Benzodiazepine receptor1995Journal of medicinal chemistry, Nov-10, Volume: 38, Issue:23
A concerted study using binding measurements, X-ray structural data, and molecular modeling on the stereochemical features responsible for the affinity of 6-arylpyrrolo[2,1-d][1,5]benzothiazepines toward mitochondrial benzodiazepine receptors.
AID779438Displacement of [3H]PK11195 from Sprague-Dawley rat kidney TSPO after 1 hr by liquid scintillation counting analysis2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Identification of a novel benzoxazolone derivative as a selective, orally active 18 kDa translocator protein (TSPO) ligand.
AID1198725Inhibition of human TSPO2015European journal of medicinal chemistry, Mar-26, Volume: 93Ether analogues of DPA-714 with subnanomolar affinity for the translocator protein (TSPO).
AID42334Binding affinity against peripheral benzodiazepine receptor( PBR).1996Journal of medicinal chemistry, Oct-11, Volume: 39, Issue:21
Molecular basis of peripheral vs central benzodiazepine receptor selectivity in a new class of peripheral benzodiazepine receptor ligands related to alpidem.
AID40086In vitro binding affinity (pIC50) was tested against peripheral benzodiazepine receptor (PBR) in rat.1997Journal of medicinal chemistry, Aug-29, Volume: 40, Issue:18
Mapping the peripheral benzodiazepine receptor binding site by conformationally restrained derivatives of 1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3- isoquinolinecarboxamide (PK11195).
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID613581Displacement of [3H]PK11195 from TSPO in rat kidney mitochondrial fraction2011Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16
Synthesis of 6-[¹⁸F]fluoro-PBR28, a novel radiotracer for imaging the TSPO 18 kDa with PET.
AID524792Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1506532Cytotoxicity against HEK293T cells expressing human wild type TSPO assessed as decrease in cell viability after 48 hrs by CellTiter blue assay2017MedChemComm, Jan-01, Volume: 8, Issue:1
Determination and reduction of translocator protein (TSPO) ligand rs6971 discrimination.
AID40229Displacement of [3H]-PK 11195 from rat peripheral (mitochondrial) benzodiazepine receptor1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
A comparative molecular field analysis model for 6-arylpyrrolo[2,1-d] [1,5]benzothiazepines binding selectively to the mitochondrial benzodiazepine receptor.
AID733069Displacement of [3H]PK11195 from TSPO in Sprague-Dawley rat kidney mitochondria after 1 hr by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Mar-01, Volume: 21, Issue:5
Design, synthesis and structure-activity relationship of novel tricyclic benzimidazolone derivatives as potent 18 kDa translocator protein (TSPO) ligands.
AID219916Stimulation of steroid (pregnenolone) biosynthesis in mouse Y-1 adrenocortical cells at 40 uM1996Journal of medicinal chemistry, Aug-30, Volume: 39, Issue:18
Synthesis, biological activity, and SARs of pyrrolobenzoxazepine derivatives, a new class of specific "peripheral-type" benzodiazepine receptor ligands.
AID389902Displacement of [3H]flunitrazepam from central benzodiazepine receptor in Sprague-Dawley rat cerebral cortex membrane by liquid scintillation counting2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
2-Phenyl-imidazo[1,2-a]pyridine compounds containing hydrophilic groups as potent and selective ligands for peripheral benzodiazepine receptors: synthesis, binding affinity and electrophysiological studies.
AID21656Calculated partition coefficient (clogP)1999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Novel 2-phenylimidazo[1,2-a]pyridine derivatives as potent and selective ligands for peripheral benzodiazepine receptors: synthesis, binding affinity, and in vivo studies.
AID672793Displacement of [3H]PK11195 from TSPO in rat kidney mitochondrial membranes by competitive binding assay2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Synthesis and biological evaluation of 4-phenylquinazoline-2-carboxamides designed as a novel class of potent ligands of the translocator protein.
AID157391In vitro inhibition of [11C]2 binding to Peripheral benzodiazepine receptor (PBR) in rat brain2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Development of a new radioligand, N-(5-fluoro-2-phenoxyphenyl)-N-(2-[18F]fluoroethyl-5-methoxybenzyl)acetamide, for pet imaging of peripheral benzodiazepine receptor in primate brain.
AID672797Antiproliferative activity against human U87MG cells assessed as cell viability at 100 uM after 24 hrs by MTS assay2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Synthesis and biological evaluation of 4-phenylquinazoline-2-carboxamides designed as a novel class of potent ligands of the translocator protein.
AID613580Displacement of [3H]PK11195 from TSPO in rat heart membrane homogenate2011Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16
Synthesis of 6-[¹⁸F]fluoro-PBR28, a novel radiotracer for imaging the TSPO 18 kDa with PET.
AID1156185Displacement of [3H]PK11195 from TSPO in rat C6 cell membrane after 90 mins by radioligand binding assay2014ACS medicinal chemistry letters, Jun-12, Volume: 5, Issue:6
Synthesis, Characterization, and in Vitro Evaluation of a New TSPO-Selective Bifunctional Chelate Ligand.
AID24191Partition coefficient of the compound2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Development of a new radioligand, N-(5-fluoro-2-phenoxyphenyl)-N-(2-[18F]fluoroethyl-5-methoxybenzyl)acetamide, for pet imaging of peripheral benzodiazepine receptor in primate brain.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1138444Induction of mitochondrial membrane depolarization in human U-343 MGa cells at 10 uM after 5 hrs by cell fluo-analyzer relative to control2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Structure-activity relationship refinement and further assessment of 4-phenylquinazoline-2-carboxamide translocator protein ligands as antiproliferative agents in human glioblastoma tumors.
AID224937Test in vitro, for potential ability to displace [3H]1 from PBR in rat brain cortex2001Journal of medicinal chemistry, Apr-12, Volume: 44, Issue:8
Mapping and fitting the peripheral benzodiazepine receptor binding site by carboxamide derivatives. Comparison of different approaches to quantitative ligand-receptor interaction modeling.
AID1198727Induction of pregnenolone production in rat C6 cells at 40 uM after 2 hrs by ELISA based steroidogenesis assay relative to control2015European journal of medicinal chemistry, Mar-26, Volume: 93Ether analogues of DPA-714 with subnanomolar affinity for the translocator protein (TSPO).
AID368140Displacement of [3H]PK11195 from TSPO2009Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3
The translocator protein (18 kDa): central nervous system disease and drug design.
AID1506534Displacement of [3H]PK11195 from human wild type TSPO expressed in HEK293T cell membranes after 90 mins by scintillation counting method2017MedChemComm, Jan-01, Volume: 8, Issue:1
Determination and reduction of translocator protein (TSPO) ligand rs6971 discrimination.
AID19017Partition coefficient (logP)2003Bioorganic & medicinal chemistry letters, Jan-20, Volume: 13, Issue:2
[18F]FMDAA1106 and [18F]FEDAA1106: two positron-emitter labeled ligands for peripheral benzodiazepine receptor (PBR).
AID363486Induction of pregnenolone biosynthesis in rat C6 cells assessed as increase in pregnenolone level at 40 uM after 2 hrs by ELISA relative to control2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Anxiolytic-like effects of N,N-dialkyl-2-phenylindol-3-ylglyoxylamides by modulation of translocator protein promoting neurosteroid biosynthesis.
AID678664Lipophilicity, log D of the compound at pH 7.42012Bioorganic & medicinal chemistry letters, Sep-15, Volume: 22, Issue:18
Exploration of the structure-activity relationship of the diaryl anilide class of ligands for translocator protein--potential novel positron emitting tomography imaging agents.
AID1506536Cytotoxicity against HEK293T cells expressing human TSPO A147T mutant assessed as decrease in cell viability after 48 hrs by CellTiter blue assay2017MedChemComm, Jan-01, Volume: 8, Issue:1
Determination and reduction of translocator protein (TSPO) ligand rs6971 discrimination.
AID277970Distribution coefficient, log D at pH 7.4 by shake flask method2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
N-(5-Fluoro-2-phenoxyphenyl)-N-(2-[(131)I]iodo-5-me thoxybenzyl)acetamide: a potent iodinated radioligand for the peripheral-type benzodiazepine receptor in brain.
AID264315Displacement of [11C](R)-PK1119 from Sprague-Dawley rat brain PBR2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
[2-11C]isopropyl-, [1-11C]ethyl-, and [11C]methyl-labeled phenoxyphenyl acetamide derivatives as positron emission tomography ligands for the peripheral benzodiazepine receptor: radiosynthesis, uptake, and in vivo binding in brain.
AID1338644Binding affinity to recombinant human TSPO by SPR assay2017European journal of medicinal chemistry, Jan-05, Volume: 125Discovery of benzimidazole derivatives as modulators of mitochondrial function: A potential treatment for Alzheimer's disease.
AID408747Displacement of [3H]PK11195 from PBR in rat kidney mitochondrial membrane2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
Synthesis, fluorine-18 radiolabeling, and in vitro characterization of 1-iodophenyl-N-methyl-N-fluoroalkyl-3-isoquinoline carboxamide derivatives as potential PET radioligands for imaging peripheral benzodiazepine receptor.
AID613582Displacement of [3H]PK11195 from TSPO in human HEK293 mitochondrial fraction2011Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16
Synthesis of 6-[¹⁸F]fluoro-PBR28, a novel radiotracer for imaging the TSPO 18 kDa with PET.
AID242260Displacement of [3H]PK11195 from peripheral benzodiazepine receptor2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Methyl pyropheophorbide-a analogues: potential fluorescent probes for the peripheral-type benzodiazepine receptor. Effect of central metal in photosensitizing efficacy.
AID1336310Displacement of [3H]PK 11195 from rat heart peripheral-type benzodiazepine receptor measured after 15 mins by scintillation counting method2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH
AID40238In vitro displacement of [11C]DAA1106 from PBR (peripheral benzodiazepine receptor) of rat brain2003Bioorganic & medicinal chemistry letters, Jan-20, Volume: 13, Issue:2
[18F]FMDAA1106 and [18F]FEDAA1106: two positron-emitter labeled ligands for peripheral benzodiazepine receptor (PBR).
AID593591Binding affinity to benzodiazepine binding site of GABAA receptor2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
N-(4-cyanotetrahydro-2H-pyran-4-yl) and N-(1-cyanocyclohexyl) derivatives of 1,5-diarylpyrazole-3-carboxamides showing high affinity for 18 kDa translocator protein and/or cannabinoid receptors.
AID39904In vitro displacement of [3H]PK11195 from the peripheral benzodiazepine receptor (PBR) in rat cortex1997Journal of medicinal chemistry, Aug-29, Volume: 40, Issue:18
Mapping the peripheral benzodiazepine receptor binding site by conformationally restrained derivatives of 1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3- isoquinolinecarboxamide (PK11195).
AID306157Induction of reactive oxygen species response in Jurkat cells at 75 uM in presence of Vitamin E after 1 hr2007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
Inhibition of the mitochondrial F1F0-ATPase by ligands of the peripheral benzodiazepine receptor.
AID275804Displacement of 2-(2-(4-fluorophenyl)-1H-indol -3-yl)-N-(6-(7-nitrobenzo[c][1, 2,5]oxadiazol-4-ylamino)hexyl )-2-oxoacetamide from peripheral type benzodiazepine receptor in rat C6 glioma cells at 10 uM2007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
New fluorescent 2-phenylindolglyoxylamide derivatives as probes targeting the peripheral-type benzodiazepine receptor: design, synthesis, and biological evaluation.
AID1236028Inhibition of [3H]PK11195 binding to TSPO in rat kidney mitochondrial membranes2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Deepening the Topology of the Translocator Protein Binding Site by Novel N,N-Dialkyl-2-arylindol-3-ylglyoxylamides.
AID415746Displacement of [11C]flumazenil from CBR receptor in rat brain membrane2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
[18F]FEAC and [18F]FEDAC: Two novel positron emission tomography ligands for peripheral-type benzodiazepine receptor in the brain.
AID125844Concentration (i.v.) was tested for time activity curve (TAC) in the occipital cortex of monkey brain2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Development of a new radioligand, N-(5-fluoro-2-phenoxyphenyl)-N-(2-[18F]fluoroethyl-5-methoxybenzyl)acetamide, for pet imaging of peripheral benzodiazepine receptor in primate brain.
AID1254854Displacement of [3H]PK11195 from TSPO receptor in Sprague-Dawley rat cerebral cortex membrane at 100 nM by radiometric competitive assay2015European journal of medicinal chemistry, Oct-20, Volume: 103Discovery of potent and selective cytotoxic activity of new quinazoline-ureas against TMZ-resistant glioblastoma multiforme (GBM).
AID306154Induction of cell death in Jurkat cells after 24 hrs2007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
Inhibition of the mitochondrial F1F0-ATPase by ligands of the peripheral benzodiazepine receptor.
AID554238Displacement of [11C]PK11195 from TSPO in rat kidney mitochondrial membrane2011Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1
Evaluation of novel N1-methyl-2-phenylindol-3-ylglyoxylamides as a new chemotype of 18 kDa translocator protein-selective ligand suitable for the development of positron emission tomography radioligands.
AID408746Binding affinity to human PBR2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
Synthesis, fluorine-18 radiolabeling, and in vitro characterization of 1-iodophenyl-N-methyl-N-fluoroalkyl-3-isoquinoline carboxamide derivatives as potential PET radioligands for imaging peripheral benzodiazepine receptor.
AID751895Binding affinity to peripheral BZD receptor (unknown origin) by radioligand displacement assay2013European journal of medicinal chemistry, May, Volume: 63Synthesis and structure-activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds.
AID1503637Binding affinity to C-terminal DDK-tagged human recombinant full-length TSPO expressed in HEK293 cells by SPR assay2017European journal of medicinal chemistry, Dec-01, Volume: 141Discovery of thienopyrrolotriazine derivatives to protect mitochondrial function against Aβ-induced neurotoxicity.
AID244082Displacement of [3H]MeTRH from Thyrotropin releasing hormone receptor 1 was measured; expressed as %2005Bioorganic & medicinal chemistry letters, Feb-01, Volume: 15, Issue:3
1-(Phenyl)isoquinoline carboxamides: a novel class of subtype selective inhibitors of thyrotropin-releasing hormone (TRH) receptors.
AID264328Decrease in uptake in iv dosed rhesus monkey brain occipital cortex after 90 mins in presence of 5 mg/kg (R)-PK11192006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
[2-11C]isopropyl-, [1-11C]ethyl-, and [11C]methyl-labeled phenoxyphenyl acetamide derivatives as positron emission tomography ligands for the peripheral benzodiazepine receptor: radiosynthesis, uptake, and in vivo binding in brain.
AID1695087Selectivity index, ratio of Ki for human TSPO A147T mutant expressed in HEK293 cell membranes to Ki for human TSPO expressed in HEK293 cell membranes2020RSC medicinal chemistry, Apr-01, Volume: 11, Issue:4
Reversing binding sensitivity to A147T translocator protein.
AID368146Displacement of [3H]PK11195 from TSPO in rat cortex2009Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3
The translocator protein (18 kDa): central nervous system disease and drug design.
AID72760Modulatory activity against human GABA-A receptor alpha-1-beta-2-gamma-2 subunits expressed in Xenopus laevis Oocytes at 50 uM1999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Novel 2-phenylimidazo[1,2-a]pyridine derivatives as potent and selective ligands for peripheral benzodiazepine receptors: synthesis, binding affinity, and in vivo studies.
AID40675Displacement of [3H]-PK 11195 from peripheral-type benzodiazepine receptor of rat ovary membranes1999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Novel 2-phenylimidazo[1,2-a]pyridine derivatives as potent and selective ligands for peripheral benzodiazepine receptors: synthesis, binding affinity, and in vivo studies.
AID461671Displacement of [3H]PK11195 from TSPO in Sprague-Dawley rat brain homogenates by liquid scintillation counting2010Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3
New iodinated quinoline-2-carboxamides for SPECT imaging of the translocator protein.
AID306151Induction of reactive oxygen species response in Ramos cells after 1 hr2007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
Inhibition of the mitochondrial F1F0-ATPase by ligands of the peripheral benzodiazepine receptor.
AID1849525Binding affinity to CBR (unknown origin)2021European journal of medicinal chemistry, Jan-01, Volume: 209An update into the medicinal chemistry of translocator protein (TSPO) ligands.
AID102218Stimulatory effect on progesterone biosynthesis in MA10 leydig cells2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Synthesis of new molecular probes for investigation of steroid biosynthesis induced by selective interaction with peripheral type benzodiazepine receptors (PBR).
AID1276954Inverse agonist activity at GST tagged-human CAR-LBD assessed as reduction in fluorescein-PGC1 alpha coactivator recruitment after 1 hr by TR-FRET assay2016European journal of medicinal chemistry, Jan-27, Volume: 108Development of CINPA1 analogs as novel and potent inverse agonists of constitutive androstane receptor.
AID72758Modulatory activity against human GABA-A receptor alpha-1-beta-2-gamma-2 subunits expressed in Xenopus laevis Oocytes at 10 uM1999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Novel 2-phenylimidazo[1,2-a]pyridine derivatives as potent and selective ligands for peripheral benzodiazepine receptors: synthesis, binding affinity, and in vivo studies.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID40673Affinity benzodiazepine receptor as ability to displace [3H]flunitrazepam from binding to membrane preparations from rat cerebral cortex.1999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Novel 2-phenylimidazo[1,2-a]pyridine derivatives as potent and selective ligands for peripheral benzodiazepine receptors: synthesis, binding affinity, and in vivo studies.
AID1209488Antagonist activity at human CAR expressed in human HepG2 cells coexpressing CYP2B6 assessed as inhibition of CITCO-induced receptor activation at 10 uM after 24 hrs by dual luciferase reporter gene assay2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Species-dependent and receptor-selective action of bilobalide on the function of constitutive androstane receptor and pregnane X receptor.
AID39929Binding affinity against peripheral-type benzodiazepine receptor (PBR) from rat cortex homogenate using [3H]-PK 11195 as radioligand1996Journal of medicinal chemistry, Aug-30, Volume: 39, Issue:18
Synthesis, biological activity, and SARs of pyrrolobenzoxazepine derivatives, a new class of specific "peripheral-type" benzodiazepine receptor ligands.
AID277959Displacement of [125I]N-(5-fluoro-2-phenoxyphenyl)-N-(2-iodo-5-methoxybenzyl)acetamide from PBR in ddy mouse cerebellum at 1 mg/kg, iv after 30 mins relative to control2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
N-(5-Fluoro-2-phenoxyphenyl)-N-(2-[(131)I]iodo-5-me thoxybenzyl)acetamide: a potent iodinated radioligand for the peripheral-type benzodiazepine receptor in brain.
AID619230Displacement of [3H]PK11195 from TSPO receptor in rat kidney membranes2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Tertiary amides with a five-membered heteroaromatic ring as new probes for the translocator protein.
AID264317Displacement of [11C]Flumazenil from Sprague-Dawley rat brain CBR2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
[2-11C]isopropyl-, [1-11C]ethyl-, and [11C]methyl-labeled phenoxyphenyl acetamide derivatives as positron emission tomography ligands for the peripheral benzodiazepine receptor: radiosynthesis, uptake, and in vivo binding in brain.
AID1254858Displacement of [3H]PK11195 from TSPO receptor in Sprague-Dawley rat cerebral cortex membrane at 0.1 nM by radiometric competitive assay2015European journal of medicinal chemistry, Oct-20, Volume: 103Discovery of potent and selective cytotoxic activity of new quinazoline-ureas against TMZ-resistant glioblastoma multiforme (GBM).
AID346405Displacement of radiolabeled PK 11195 from peripheral-type benzodiazepine receptor2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.
AID277911Displacement of [11C]PK-11195 from PBR in Sprague-Dawley rat brain2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
N-(5-Fluoro-2-phenoxyphenyl)-N-(2-[(131)I]iodo-5-me thoxybenzyl)acetamide: a potent iodinated radioligand for the peripheral-type benzodiazepine receptor in brain.
AID40674Displacement of [3H]-PK 11195 from peripheral-type benzodiazepine receptor of rat cerebral cortex membranes1999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Novel 2-phenylimidazo[1,2-a]pyridine derivatives as potent and selective ligands for peripheral benzodiazepine receptors: synthesis, binding affinity, and in vivo studies.
AID40100Displacement of [3H]-PK 11195 from peripheral (mitochondrial) benzodiazepine receptor1994Journal of medicinal chemistry, May-13, Volume: 37, Issue:10
Novel ligands specific for mitochondrial benzodiazepine receptors: 6-arylpyrrolo[2,1-d][1,5]benzothiazepine derivatives. Synthesis, structure-activity relationships, and molecular modeling studies.
AID1894700Activation of TSPO in rat C6 glioma cells assessed as increase in pregnenolone incubated for 2 hrs by radioimmuno assay2021Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
The Alpha Keto Amide Moiety as a Privileged Motif in Medicinal Chemistry: Current Insights and Emerging Opportunities.
AID1894698Displacement of [3H]-PK11195 from rat kidney mitochondrial membrane TSPO receptor assessed as inhibition constant2021Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
The Alpha Keto Amide Moiety as a Privileged Motif in Medicinal Chemistry: Current Insights and Emerging Opportunities.
AID264318Distribution coefficient of the compound, log D2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
[2-11C]isopropyl-, [1-11C]ethyl-, and [11C]methyl-labeled phenoxyphenyl acetamide derivatives as positron emission tomography ligands for the peripheral benzodiazepine receptor: radiosynthesis, uptake, and in vivo binding in brain.
AID1849527Selectivity ratio of Ki for CBR (unknown origin) to Ki for TSPO receptor in Wistar rat brain2021European journal of medicinal chemistry, Jan-01, Volume: 209An update into the medicinal chemistry of translocator protein (TSPO) ligands.
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID678672Ratio of high binding affinity to low affinity site at TSPO in human platelets2012Bioorganic & medicinal chemistry letters, Sep-15, Volume: 22, Issue:18
Exploration of the structure-activity relationship of the diaryl anilide class of ligands for translocator protein--potential novel positron emitting tomography imaging agents.
AID306150Inhibition of F1F0-ATPase synthesis activity in bovine submitochondrial particles2007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
Inhibition of the mitochondrial F1F0-ATPase by ligands of the peripheral benzodiazepine receptor.
AID125843Concentration (i.v.) was tested for reduction of radioactivity in the occipital cortex of monkey brain2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Development of a new radioligand, N-(5-fluoro-2-phenoxyphenyl)-N-(2-[18F]fluoroethyl-5-methoxybenzyl)acetamide, for pet imaging of peripheral benzodiazepine receptor in primate brain.
AID593590Displacement of [3H]PK11195 from TSPO receptor in rat kidney membranes2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
N-(4-cyanotetrahydro-2H-pyran-4-yl) and N-(1-cyanocyclohexyl) derivatives of 1,5-diarylpyrazole-3-carboxamides showing high affinity for 18 kDa translocator protein and/or cannabinoid receptors.
AID1506533Selectivity ratio of Ki for human TSPO A147T mutant to Ki for human wild type TSPO2017MedChemComm, Jan-01, Volume: 8, Issue:1
Determination and reduction of translocator protein (TSPO) ligand rs6971 discrimination.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1695086Displacement of [3H]PK11195 from wild-type human TSPO expressed in HEK293 cell membranes after 90 mins by scintillation counting method2020RSC medicinal chemistry, Apr-01, Volume: 11, Issue:4
Reversing binding sensitivity to A147T translocator protein.
AID1236029Inhibition of [3H]flumazenil binding to benzodiazepine receptor in rat cerebral cortex membranes at 10 uM incubated for 90 mins2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Deepening the Topology of the Translocator Protein Binding Site by Novel N,N-Dialkyl-2-arylindol-3-ylglyoxylamides.
AID275802Displacement of [3H]PK 11195 from peripheral-type benzodiazepine receptor in rat kidney mitochondrial membranes2007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
New fluorescent 2-phenylindolglyoxylamide derivatives as probes targeting the peripheral-type benzodiazepine receptor: design, synthesis, and biological evaluation.
AID1695085Displacement of [3H]PK11195 from human TSPO A147T mutant expressed in HEK293 cells after 90 mins by scintillation counting method2020RSC medicinal chemistry, Apr-01, Volume: 11, Issue:4
Reversing binding sensitivity to A147T translocator protein.
AID516406Displacement of [3H]Ro151788 from CBR in rat kidney2010Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19
Pyrazolo[1,5-a]pyrimidine acetamides: 4-Phenyl alkyl ether derivatives as potent ligands for the 18 kDa translocator protein (TSPO).
AID1254855Displacement of [3H]PK11195 from TSPO receptor in Sprague-Dawley rat cerebral cortex membrane at 10 nM by radiometric competitive assay2015European journal of medicinal chemistry, Oct-20, Volume: 103Discovery of potent and selective cytotoxic activity of new quinazoline-ureas against TMZ-resistant glioblastoma multiforme (GBM).
AID277910Displacement of [11C]DAA1106 from PBR in Sprague-Dawley rat brain2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
N-(5-Fluoro-2-phenoxyphenyl)-N-(2-[(131)I]iodo-5-me thoxybenzyl)acetamide: a potent iodinated radioligand for the peripheral-type benzodiazepine receptor in brain.
AID306158Induction of cell death in Jurkat cells at 75 uM after 24 hrs2007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
Inhibition of the mitochondrial F1F0-ATPase by ligands of the peripheral benzodiazepine receptor.
AID752256Binding affinity to peripheral-type BZD receptor (unknown origin) by radioligand displacement assay2013Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10
Synthesis and biological evaluation of 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamide stereoisomers as novel positive allosteric modulators of sigma-1 receptor.
AID306152Induction of reactive oxygen species response in Jurkat cells after 1 hr2007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
Inhibition of the mitochondrial F1F0-ATPase by ligands of the peripheral benzodiazepine receptor.
AID1506535Displacement of [3H]PK11195 from human TSPO A147T mutant expressed in HEK293T cell membranes after 90 mins by scintillation counting method2017MedChemComm, Jan-01, Volume: 8, Issue:1
Determination and reduction of translocator protein (TSPO) ligand rs6971 discrimination.
AID1503636Displacement of [3H]PK11195 from TSPO in Sprague-Dawley rat cerebral cortex membranes after 60 mins by liquid scintillation counting analysis2017European journal of medicinal chemistry, Dec-01, Volume: 141Discovery of thienopyrrolotriazine derivatives to protect mitochondrial function against Aβ-induced neurotoxicity.
AID678665Displacement of [3H]PK11195 from TSPO in Wistar rat heart incubated for 15 mins2012Bioorganic & medicinal chemistry letters, Sep-15, Volume: 22, Issue:18
Exploration of the structure-activity relationship of the diaryl anilide class of ligands for translocator protein--potential novel positron emitting tomography imaging agents.
AID39907Inhibitory activity against specific binding of [3H]-CB 34 to peripheral benzodiazepine receptor in rat cortical membranes was evaluated2003Journal of medicinal chemistry, Aug-14, Volume: 46, Issue:17
Structure-activity relationships in carboxamide derivatives based on the targeted delivery of radionuclides and boron atoms by means of peripheral benzodiazepine receptor ligands.
AID1338613Inhibition of TSPO (unknown origin)2017European journal of medicinal chemistry, Jan-05, Volume: 125Discovery of benzimidazole derivatives as modulators of mitochondrial function: A potential treatment for Alzheimer's disease.
AID1254853Displacement of [3H]PK11195 from TSPO receptor in Sprague-Dawley rat cerebral cortex membrane at 1 uM by radiometric competitive assay2015European journal of medicinal chemistry, Oct-20, Volume: 103Discovery of potent and selective cytotoxic activity of new quinazoline-ureas against TMZ-resistant glioblastoma multiforme (GBM).
AID389906Agonist activity at human recombinant GABAA alpha-1-beta-2-gamma-2L receptor expressed in Xenopus oocytes assessed as change in GABA-induced chloride current amplitude at 10 uM by voltage clamp technique2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
2-Phenyl-imidazo[1,2-a]pyridine compounds containing hydrophilic groups as potent and selective ligands for peripheral benzodiazepine receptors: synthesis, binding affinity and electrophysiological studies.
AID306159Induction of cell death in Jurkat cells at 75 uM in presence of Mn(III)tetrakis(4-benzoic acid)porphyrin after 24 hrs2007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
Inhibition of the mitochondrial F1F0-ATPase by ligands of the peripheral benzodiazepine receptor.
AID672795Displacement of [3H]flumazenil from central benzodiazepine receptor in rat cerebral cortex membranes at 10 uM after 90 mins by competitive binding assay2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Synthesis and biological evaluation of 4-phenylquinazoline-2-carboxamides designed as a novel class of potent ligands of the translocator protein.
AID1338645Inhibition of TSPO in mouse HT22 cells assessed as inhibition of amyloid beta (1 to 42)-induced mitochondrial permeability transition pore opening by measuring decrease in intracellular calcium level after 30 mins by Fura-2-AM dye based fluorescence assay2017European journal of medicinal chemistry, Jan-05, Volume: 125Discovery of benzimidazole derivatives as modulators of mitochondrial function: A potential treatment for Alzheimer's disease.
AID52213In vitro inhibition of [11C]flumazenil binding to GABA-A central benzodiazepine receptor of rat brain2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Development of a new radioligand, N-(5-fluoro-2-phenoxyphenyl)-N-(2-[18F]fluoroethyl-5-methoxybenzyl)acetamide, for pet imaging of peripheral benzodiazepine receptor in primate brain.
AID1138439Displacement of [3H]PK11195 from TSPO in rat kidney mitochondrial membranes2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Structure-activity relationship refinement and further assessment of 4-phenylquinazoline-2-carboxamide translocator protein ligands as antiproliferative agents in human glioblastoma tumors.
AID72759Modulatory activity against human GABA-A receptor alpha-1-beta-2-gamma-2 subunits expressed in Xenopus laevis Oocytes at 100 uM1999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Novel 2-phenylimidazo[1,2-a]pyridine derivatives as potent and selective ligands for peripheral benzodiazepine receptors: synthesis, binding affinity, and in vivo studies.
AID39906Inhibition of binding of [3H]-PK 11195 to peripheral-type benzodiazepine receptor (PBR) from rat cortex homogenate1996Journal of medicinal chemistry, Aug-30, Volume: 39, Issue:18
Synthesis, biological activity, and SARs of pyrrolobenzoxazepine derivatives, a new class of specific "peripheral-type" benzodiazepine receptor ligands.
AID1254856Displacement of [3H]PK11195 from TSPO receptor in Sprague-Dawley rat cerebral cortex membrane at 1 nM by radiometric competitive assay2015European journal of medicinal chemistry, Oct-20, Volume: 103Discovery of potent and selective cytotoxic activity of new quinazoline-ureas against TMZ-resistant glioblastoma multiforme (GBM).
AID415747Distribution coefficient, log D in octanol/phosphate buffer at pH 7.4 by shaking flask method2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
[18F]FEAC and [18F]FEDAC: Two novel positron emission tomography ligands for peripheral-type benzodiazepine receptor in the brain.
AID415744Displacement of [11C]PK11195 from PBR receptor in rat brain membrane2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
[18F]FEAC and [18F]FEDAC: Two novel positron emission tomography ligands for peripheral-type benzodiazepine receptor in the brain.
AID277958Displacement of [125I]N-(5-fluoro-2-phenoxyphenyl)-N-(2-iodo-5-methoxybenzyl)acetamide from PBR in ddy mouse olfactory bulb at 1 mg/kg, iv after 30 mins relative to control2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
N-(5-Fluoro-2-phenoxyphenyl)-N-(2-[(131)I]iodo-5-me thoxybenzyl)acetamide: a potent iodinated radioligand for the peripheral-type benzodiazepine receptor in brain.
AID570603Displacement of [3H]-PK11195 from PBR after 1 hr by scintillation counting2011ACS medicinal chemistry letters, Feb-10, Volume: 2, Issue:2
TSPO 18 kDa (PBR) Targeted Photosensitizers for Cancer Imaging (PET) and PDT.
AID306149Inhibition of F1F0-ATPase hydrolysis activity in bovine submitochondrial particles2007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
Inhibition of the mitochondrial F1F0-ATPase by ligands of the peripheral benzodiazepine receptor.
AID389905Agonist activity at human recombinant GABAA alpha-1-beta-2-gamma-2L receptor expressed in Xenopus oocytes assessed as change in GABA-induced chloride current amplitude at 1 uM by voltage clamp technique2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
2-Phenyl-imidazo[1,2-a]pyridine compounds containing hydrophilic groups as potent and selective ligands for peripheral benzodiazepine receptors: synthesis, binding affinity and electrophysiological studies.
AID264316Displacement of [11C]DAA1106 from Sprague-Dawley rat brain PBR2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
[2-11C]isopropyl-, [1-11C]ethyl-, and [11C]methyl-labeled phenoxyphenyl acetamide derivatives as positron emission tomography ligands for the peripheral benzodiazepine receptor: radiosynthesis, uptake, and in vivo binding in brain.
AID1506538Antiproliferative activity against HEK293T cells expressing human wild type TSPO after 48 hrs by BrdU incorporation assay2017MedChemComm, Jan-01, Volume: 8, Issue:1
Determination and reduction of translocator protein (TSPO) ligand rs6971 discrimination.
AID1506537Selectivity ratio of IC50 for HEK293T cells expressing human TSPO A147T mutant assessed as decrease in cell viability to IC50 for HEK293T cells expressing human wild type TSPO assessed as decrease in cell viability2017MedChemComm, Jan-01, Volume: 8, Issue:1
Determination and reduction of translocator protein (TSPO) ligand rs6971 discrimination.
AID1138443Cytotoxicity against human U-343 MGa cells assessed as inhibition of cell survival at 100 uM after 24 hrs by colorimetric viability MTS assay2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Structure-activity relationship refinement and further assessment of 4-phenylquinazoline-2-carboxamide translocator protein ligands as antiproliferative agents in human glioblastoma tumors.
AID306160Induction of cell death in Jurkat cells at 75 uM in presence of Vitamin E after 24 hrs2007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
Inhibition of the mitochondrial F1F0-ATPase by ligands of the peripheral benzodiazepine receptor.
AID1849526Displacement of [3H]-flunitrazepam from TSPO receptor in Wistar rat brain without cerebellum incubated for 90 mins by liquid scintillation counter analysis2021European journal of medicinal chemistry, Jan-01, Volume: 209An update into the medicinal chemistry of translocator protein (TSPO) ligands.
AID389903Displacement of [3H]PK11195 from peripheral benzodiazepine receptor in Sprague-Dawley rat cerebral cortex membrane by liquid scintillation counting2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
2-Phenyl-imidazo[1,2-a]pyridine compounds containing hydrophilic groups as potent and selective ligands for peripheral benzodiazepine receptors: synthesis, binding affinity and electrophysiological studies.
AID306153Induction of cell death in Ramos cells after 24 hrs2007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
Inhibition of the mitochondrial F1F0-ATPase by ligands of the peripheral benzodiazepine receptor.
AID1254857Displacement of [3H]PK11195 from TSPO receptor in Sprague-Dawley rat cerebral cortex membrane by radiometric competitive assay2015European journal of medicinal chemistry, Oct-20, Volume: 103Discovery of potent and selective cytotoxic activity of new quinazoline-ureas against TMZ-resistant glioblastoma multiforme (GBM).
AID40374Binding affinity to peripheral benzodiazepine receptors using [3H]-PK11195 radioligand in rat kidney mitochondrial membrane2004Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7
N,N-dialkyl-2-phenylindol-3-ylglyoxylamides. A new class of potent and selective ligands at the peripheral benzodiazepine receptor.
AID1506539Antiproliferative activity against HEK293T cells expressing human TSPO A147T mutant after 48 hrs by BrdU incorporation assay2017MedChemComm, Jan-01, Volume: 8, Issue:1
Determination and reduction of translocator protein (TSPO) ligand rs6971 discrimination.
AID1198724Inhibition of rat TSPO2015European journal of medicinal chemistry, Mar-26, Volume: 93Ether analogues of DPA-714 with subnanomolar affinity for the translocator protein (TSPO).
AID270650Cytotoxicity against rat C6 glioma cell line2006Journal of medicinal chemistry, Sep-21, Volume: 49, Issue:19
Discovery of antiglioma activity of biaryl 1,2,3,4-tetrahydroisoquinoline derivatives and conformationally flexible analogues.
AID306155Induction of reactive oxygen species response in Jurkat cells at 75 uM after 1 hr2007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
Inhibition of the mitochondrial F1F0-ATPase by ligands of the peripheral benzodiazepine receptor.
AID516405Displacement of [3H]PK11195 from TSPO in rat kidney2010Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19
Pyrazolo[1,5-a]pyrimidine acetamides: 4-Phenyl alkyl ether derivatives as potent ligands for the 18 kDa translocator protein (TSPO).
AID165929Lymphotoxic activity against immortalized Ramos B cells in culture2003Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19
Structure activity studies of a novel cytotoxic benzodiazepine.
AID1285618Displacement of [3H]PK 11195 from rat heart Peripheral-type benzodiazepine receptor2016Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8
Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1645848NCATS Kinetic Aqueous Solubility Profiling2019Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
AID493017Wombat Data for BeliefDocking2005Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1
Structure-activity relationships and effects on neuroactive steroid synthesis in a series of 2-phenylimidazo[1,2-a]pyridineacetamide peripheral benzodiazepine receptors ligands.
AID1508591NCATS Rat Liver Microsome Stability Profiling2020Scientific reports, 11-26, Volume: 10, Issue:1
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
AID1508612NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Highly predictive and interpretable models for PAMPA permeability.
AID1798152Radioligand Binding Assay from Article 10.1021/jm061137o: \\New fluorescent 2-phenylindolglyoxylamide derivatives as probes targeting the peripheral-type benzodiazepine receptor: design, synthesis, and biological evaluation.\\2007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
New fluorescent 2-phenylindolglyoxylamide derivatives as probes targeting the peripheral-type benzodiazepine receptor: design, synthesis, and biological evaluation.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,039)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990127 (12.22)18.7374
1990's297 (28.59)18.2507
2000's325 (31.28)29.6817
2010's251 (24.16)24.3611
2020's39 (3.75)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.92

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.92 (24.57)
Research Supply Index6.98 (2.92)
Research Growth Index4.72 (4.65)
Search Engine Demand Index34.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.92)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials11 (1.03%)5.53%
Reviews40 (3.76%)6.00%
Case Studies13 (1.22%)4.05%
Observational0 (0.00%)0.25%
Other999 (93.98%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Mayo Clinic Health System-wide Neurological, Vascular and Neurovascular Events With SARS-CoV-2- Part II [NCT05220514]100 participants (Anticipated)Observational2022-01-19Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]